TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03423875

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PrEDICT game score
Description: PrEDICT game score will be shared with the emergency physicians and health care professionals
Study: NCT00347100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Glargine
Description: Throughout study period

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glyburide
Description: Combination throughout the study period. Titrate to FPG ≤ 100 mg/dl.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glyclazide
Description: Combination throughout the study period. Titrate to FPG ≤ 100 mg/dl.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimiperide
Description: Combination throughout the study period. Titrate to FPG ≤ 100 mg/dl.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glipizide
Description: Combination throughout the study period. Titrate to FPG ≤ 100 mg/dl.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Combination throughout the study period. Titrate to FPG ≤ 100 mg/dl.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Combination throughout the study period. Titrate to FPG ≤ 100 mg/dl.
Study: NCT02055703

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: E2609

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: E2609

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: E2609

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: E2609

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: itraconazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rifampin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: digoxin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: donepezil
Study: NCT03117517

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin (1000 mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin, Pioglitazone
Description: Metformin (1000 mg) Pioglitazone (30 mg)
Study: NCT02110446

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SS-1
Description: The patients will be divided into two groups (A and B) at random and all of them keep the routine treatment in the rheumatology OPD. Group A patients will receive 12 weeks SS-1 treatment first, and then stop the SS-1 for 4 weeks for wash-out phase, and then receive 12weeks placebo treatment. Group B patients receive 12 weeks placebo first, and then stop the placebo treatment for 4 weeks for wash-out phase, and then receive 12weeks SS-1 treatment.~SS-1 is composed of 3 traditional Chinese herbal formula: Gan-Lu-Yin, Sang-Ju-Yin and Xuefu-Zhuyu-Decoction with the ratio of 2:1:1. The placebo is composed with corn starch, pigment and minimal dose of 1% SS-1. Patients in both groups take 6 gram of SS-1/Placebo three times per day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo is composed of corn starch, pigment and minimal dose of 1% SS-1. Patients take 6 gram of experiment medicine three times per day.
Study: NCT04087798

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control-EDI
Description: Patients in the control group will receive Control-EDI from their primary care provider during clinic visit. Subsequent patient CKD education and follow-up will be provider dependent. Patients will be called and reminded of their study visits at 1, 6, 12 months to complete study measures, BP checks, and give urine and blood samples (baseline and 12-month visit only).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention-EDI and health coaching
Description: Patients in the intervention group will receive a personalized Intervention-EDI from their primary care provider during visit, which will include their most recent BP, their urine protein level and most recent eGFR. There is also a space for their provider to type in a sentence about specific goals for the patient.~Health coaches will conduct a baseline call and 4-6 coaching calls, based on patient's needs, over an 11-month period. There are 4 topic areas related to blood pressure and CKD that will be the focus of the calls. Coaches will also have pre-determined and vetted educational resources to provide patients if needed. Additionally, patients will be called and reminded of their study visits at 1, 6, 12 months to complete study measures, BP checks, and give urine and blood samples (baseline and 12-month visit only).
Study: NCT04449133

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD128
Description: Oral administration of two capsules before sleep for 7 days.
Study: NCT03737708

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: abatacept
Description: Administered by intravenous injection
Study: NCT00766896

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin (platelet sensitive versus platelet hyperreactivity)
Description: The dose of aspirin to be prescribed in this study will be 300 mg orally or by nasogastric tube once a day (assisted therapy), with first dose tomography soon after admission if the patient has no indication of thrombolytic therapy. After the acute phase, patients will receive aspirin at a dose of 200 mg/day. Aspirin will be administered in a simple preparation (no buffer, no extended release).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin (platelet sensitive versus platelet hyperreactivity)
Description: The dose of aspirin to be prescribed in this study will be 300 mg orally or by nasogastric tube once a day (assisted therapy), with first dose tomography soon after admission if the patient has no indication of thrombolytic therapy. After the acute phase, patients will receive aspirin at a dose of 200 mg/day. Aspirin will be administered in a simple preparation (no buffer, no extended release).
Study: NCT00814515

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NOVA22007 (Ciclosporin 0.1%)
Description: Ciclosporin 0.1% Ophthalmic Emulsions

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NOVA22007
Description: Vehicle
Study: NCT00791115

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: whole-mount sectioning of the prostate
Description: A standard open retropubic radical prostatectomy will be performed. Whole fresh prostate is be embedded in gel and oriented in the anatomic position in a plastic cylinder using wood skewers. Standard pathology reports are generated from this tissue
Study: NCT02569450

Intervention type: BEHAVIORAL
Intervention: Surgical outcomes monitoring using Shewhart control chart
Description: * Assistance by a local surgeon responsible for the implementation of intervention within his/her department~* Quarterly team meeting to interpret variations in observed outcomes on the control charts~* Restitution of surgical outcomes based on wall posters in operating room~* Training sessions provided to local surgeon for appropriate control chart utilization
Study: NCT00874653

Intervention type: DRUG
Intervention: Levonorgestrel (Mirena, BAY86-5028)
Description: Women using Mirena for intrauterine treatment of menorrhagia
Study: NCT04358341

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: 150 mg/m2 ivdrip every 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DOXOrubicin Liposome Injection
Description: 25 mg/m2 ivdrip every 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5fluorouracil
Description: 400mg/m2 iv bolus and 2400 mg/m2 civ 46h every 14 days
Study: NCT04853901

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remdesivir
Description: Remdesivir loading dose of 200 mg intravenously followed by 100 mg/day intravenously for 5 to 10days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care_1
Description: Hydroxycoloroquine 400mg twice on day 1 then 200mg tab twice 2-10 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care_2
Description: Methylprednisolone 1-2mg/kg for 5-7 days
Study: NCT02083003

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Polyamine low-diet

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Liberal alimentation
Study: NCT01486602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Defined per the protocol
Study: NCT00917267

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exenatide once weekly
Description: 2.0mg subcutaneous injection, once a week

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: exenatide twice daily
Description: 5mcg subcutaneous injection twice a day (4 weeks), 10mcg subcutaneous injection twice a day (22 weeks)
Study: NCT00404534

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin, Clarythromycin, Omeprazole for ten days
Description: Amoxicillin 1000 mg BID, clarythromycin 500 mg BID for ten days in the experimental group and placebo of Amoxicillin 1000 mg BID and placebo of clarythromycin 500 mg BID in the placebo comparator. Both groups receive omeprazole 20 mg bid for 10 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Amoxicillin, Clarythromycin, Omeprazole for ten days
Description: Amoxicillin 1000 mg BID, clarythromycin 500 mg BID for ten days in the experimental group and placebo of Amoxicillin 1000 mg BID and placebo of clarythromycin 500 mg BID in the placebo comparator. Both groups receive omeprazole 20 mg bid for 10 days.
Study: NCT01532180

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: aura6000 System
Description: The aura6000 device is an implanted hypoglossal nerve stimulator designed to maintain wakeful muscle tone of the tongue during sleep. It is implanted through a short surgical procedure. The implant is programmed to provide the optimal stimulation parameters for the patient. The therapy is controlled by a hand-held remote control allowing the patient to start, stop, and pause the therapy during times of sleep.
Study: NCT03218761

Intervention type: DIAGNOSTIC_TEST
Intervention: NET mRNA level
Description: quantification of mRNA to the Norepinephrine Transporter (NET)

Intervention type: DIAGNOSTIC_TEST
Intervention: NET mRNA level
Description: quantification of mRNA to the Norepinephrine Transporter (NET)

Intervention type: DIAGNOSTIC_TEST
Intervention: Plasma catechols
Description: plasma for assay of norepinephrine (NE), DHPG (intraneuronal metabolite of NE), and other catechols

Intervention type: DIAGNOSTIC_TEST
Intervention: Plasma catechols
Description: plasma for assay of norepinephrine (NE), DHPG (intraneuronal metabolite of NE), and other catechols

Intervention type: DIAGNOSTIC_TEST
Intervention: Urine Catechols
Description: urine for assay of norepinephrine (NE), DHPG (intraneuronal metabolite of NE), and other catechols

Intervention type: DIAGNOSTIC_TEST
Intervention: Urine Catechols
Description: urine for assay of norepinephrine (NE), DHPG (intraneuronal metabolite of NE), and other catechols
Study: NCT06350461

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Discontinuation of hypertonic saline (HS)
Description: Discontinuation of current hypertonic saline (HS) therapy during 6-week study period.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Continuation of hypertonic saline (HS)
Description: Continuation of current hypertonic saline (HS) therapy during 6-week study period. Therapy is taken at least once daily according to each participant's pre-existing, clinically prescribed regimen (e.g., daily, twice daily). The concentration of HS is according to clinical prescription (e.g., 7% sodium chloride or 3.5% sodium chloride) and at least 3%.
Study: NCT00558662

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Coban 2
Description: Bandages will be changed after a wear time of seven days, or in case of product or non-product related reason, which would require a dressing or bandage change.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SSB
Description: Bandages will be changed after a wear time of seven days, or in case of product or non-product related reason, which would require a dressing or bandage change.
Study: NCT03128437

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: At each of the six exposure sessions, participants will be invited to engage in 2-minute warm-up on the treadmill. Following this warm-up period, participants will be asked to briskly walk or jog on the treadmill at a speed that maintains their heart rate at 60-80% of maximum age-predicted heart rate for 20 minutes using the formula: (220-age) x (0.60 \[lower bound\] or 0.80 \[upper bound\]). Participants will be fitted with a heart rate monitor, which will be checked by a research assistant at 5-minute intervals in order to ensure adherence to this prescription; participants will be asked to adjust treadmill speed in order to remain in this range. Following each 20-minute exposure, participants will complete 5 minutes of cool down walking on the treadmill. Assessments will take place at baseline, week 2 (post-intervention), week 4, and week 8.
Study: NCT00665990

Intervention type: DRUG
Group type: OTHER
Intervention: Bevacizumab
Description: Bevacizumab starting dose of 5 mg/kg every 3 weeks increasing in combination with Sorafenib and Cyclophosphamide until maximum tolerated dose

Intervention type: DRUG
Group type: OTHER
Intervention: Sorafenib
Description: Sorafenib 90 mg/m2 PO every 12 hours increasing in combination with Bevacizumab and Cyclophosphamide until maximum tolerated dose

Intervention type: DRUG
Group type: OTHER
Intervention: Cyclophosphamide
Description: Cyclophosphamide 50 mg/m2 PO once daily increasing in combination with Bevacizumab and Sorafenib until maximum tolerated dose
Study: NCT02936037

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MD1003 100mg capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: an inactive substance
Study: NCT02732093

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: stellate block

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: stellate block

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Na.Cl 0.9% (placebo)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine 2%
Study: NCT02726061

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based psychological support
Description: A behavioral therapy called Problem Solving Therapy, conflict management training, and stress management training will be administered via an interactive multimedia program (PATH) to participants referred from their Employee Assistance Program and the general public for the management of depression, stress, and conflict.
Study: NCT02942680

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acetylsalicylic acid started for 24 hours before surgery

Intervention type: DRUG
Group type: OTHER
Intervention: acetylsalicylic acid stayed for 5 days before surgery
Study: NCT02778191

Intervention type: DRUG
Intervention: cisplatin
Description: 100 mg/m2 day 1, 22 and 43

Intervention type: DRUG
Intervention: carboplatin
Description: carboplatin 300-350 mg/m2 day 1, 22 and 43

Intervention type: DRUG
Intervention: 5-FU
Description: 5-FU 600 mg/m2 days 1-4, 22-25 and 43-46
Study: NCT02405117

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LiveWell System
Description: For 16 weeks, participants will be asked to carry a mobile phone and wear a wrist-worn device for measuring activity. Participants in this arm will receive the psychosocial intervention via a smartphone and context-dependent feedback based on self-report and behavioral data. Providers whose patients are randomized to this arm will also be asked to enroll in order to receive information and notifications about patient status for the duration of the study
Study: NCT02746757

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Remote conditioning

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Remote conditioning

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exendin 9-39
Study: NCT02129816

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bryophyllum

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bryophyllum

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bryophyllum
Study: NCT03408834

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: pulse variability index
Description: fluid management with pulse variability index or conventional

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: pulse variability index
Description: fluid management with pulse variability index or conventional
Study: NCT04691713

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Targeting CD276 autologous chimeric antigen receptor T cells
Description: Chimeric antigen receptor T cells (car-t) is one of the most effective therapies for malignant tumors (especially hematological tumors). Like other immunotherapies, the basic principle is to use the patient's own immune cells to clear cancer cells. Chimeric antigen receptor (car) is the core component of car-t, which endows T cells with the ability to recognize tumor antigens in an independent manner, which enables car modified T cells to recognize a wider range of targets than natural T cell surface receptors (TCR). The basic design of car includes a tumor associated antigen binding region (usually derived from scFv segment of monoclonal antibody antigen binding region), transmembrane region and intracellular signal region. The selection of target antigen is a key determinant for the specificity and effectiveness of car and the safety of genetically modified T cells.
Study: NCT04066985

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Growth Mindset Online Single-Session Program
Description: 30minute self-administered program for youths
Study: NCT02836964

Intervention type: DEVICE
Intervention: Crown placement
Description: Dental implant

Intervention type: DEVICE
Intervention: Crown placement
Description: Dental implant
Study: NCT04066985

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Kindness Online Single-Session Program
Description: 30minute self-administered program for youths

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Therapy Online Single-Session Program (Control)
Description: 30minute self-administered active comparator program for youths
Study: NCT01228344

Intervention type: OTHER
Intervention: Artemether-lumefantrine
Study: NCT02762981

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relacorilant with nab-paclitaxel
Description: Relacorilant is supplied as capsules for oral dosing. Nab-paclitaxel administered as an IV infusion.
Study: NCT03768999

Intervention type: DIAGNOSTIC_TEST
Intervention: Non-contrast magnetic resonance coronary angiography (MRCA)
Description: Scan non-contrast MRCA and compare the image with clinically scanned coronary computed tomography angiography (CTA).
Study: NCT02106689

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Needle free system
Description: Approximately 60 patients will be randomized in a 1:1 ratio to either receive their gonadotropin injections using the Comfort-in™ needle free system (treatment group), or through the standard needle and syringe (control group).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard needle injection system
Description: Approximately 60 patients will be randomized in a 1:1 ratio to either receive their gonadotropin injections using the Comfort-in™ needle free system (treatment group), or through the standard needle and syringe (control group).
Study: NCT04249336

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoro-Calcium-Phospho-Silicate based dentifrices
Description: Bio-Active glass based formulation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 8% Arginine based dentifrices
Description: Tubular occluding formulation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 8% Strontium Acetate
Description: Tubular occluding formulation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Fluoride
Description: No claim of relieving Dentin Hypersensitivity
Study: NCT00937170

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zimmer LPS flex Gender Specific Implant (Total knee replacement)
Description: Outcomes comparison between a gender specific total knee implant, a standard total knee implant by the same company, and a standard total knee implant from another company

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Zimmer High Flex LPS Implant (Total knee replacement)
Description: Outcomes comparison between a gender specific total knee implant, a standard total knee implant by the same company, and a standard total knee implant from another company

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Stryker Triathlon Implant (Total knee replacement)
Description: Outcomes comparison between a gender specific total knee implant, a standard total knee implant by the same company, and a standard total knee implant from another company
Study: NCT04373915

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Remote Bedside Rounding
Description: Parents of infants on the medical team utilizing remote rounding will have the opportunity to participate in rounds by video conferencing at the infant's bedside. Participation will be tracked and surveys regarding stress, satisfaction, and attachment will be completed by parents in both groups.
Study: NCT02127320

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe 10mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe 10mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe 10mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe 10mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe 10mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe 10mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20mg + Ezetimibe 10mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20mg + Ezetimibe 10mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20mg + Ezetimibe 10mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20mg + Ezetimibe 10mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20mg + Ezetimibe 10mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20mg + Ezetimibe 10mg